کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
11010760 | 1806343 | 2018 | 23 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Open access? Widening access to chimeric antigen receptor (CAR) therapy for ALL
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
T cells that are genetically modified to express chimeric antigen receptors (CARs) specific for CD19 show great promise for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL). The first U.S. Food and Drug Administration approval of a cellular cancer therapy in 2017, Novartis's CD19-targeting CAR T-cell product Kymriah⢠within the context of relapsed/refractory pediatric ALL, followed rapidly by approval of Kite's Yescarta⢠and, more recently, Kymriah⢠for diffuse large B-cell indications in adults, highlights the pace of progress made in this field. In this review, we will consider the latest evidence from CAR T-cell therapy for B-lineage ALL. We discuss the barriers to CAR T-cell therapy for ALL patients and give a perspective on the strategy we have taken to date to widen access to CAR T-cell therapy for UK pediatric patients with high-risk ALL.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Experimental Hematology - Volume 66, October 2018, Pages 5-16
Journal: Experimental Hematology - Volume 66, October 2018, Pages 5-16
نویسندگان
Sara Ghorashian, Persis Amrolia, Paul Veys,